Sökning: onr:"swepub:oai:DiVA.org:uu-506588" > Cross-reactive EBNA...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05256naa a2200505 4500 | |
001 | oai:DiVA.org:uu-506588 | |
003 | SwePub | |
008 | 230628s2023 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:152861661 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5065882 URI |
024 | 7 | a https://doi.org/10.1126/sciadv.adg30322 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1528616612 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Thomas, Olivia G.u Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
245 | 1 0 | a Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis |
264 | 1 | b American Association for the Advancement of Science (AAAS),c 2023 |
338 | a electronic2 rdacarrier | |
520 | a Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, for which and Epstein-Barr virus (EBV) infection is a likely prerequisite. Due to the homology between Epstein-Barr nuclear antigen 1 (EBNA1) and alpha-crystallin B (CRYAB), we examined antibody reactivity to EBNA1 and CRYAB peptide libraries in 713 persons with MS (pwMS) and 722 matched controls (Con). Antibody response to CRYAB amino acids 7 to 16 was associated with MS (OR = 2.0), and combination of high EBNA1 responses with CRYAB positivity markedly in-creased disease risk (OR = 9.0). Blocking experiments revealed antibody cross-reactivity between the homolo-gous EBNA1 and CRYAB epitopes. Evidence for T cell cross-reactivity was obtained in mice between EBNA1 and CRYAB, and increased CRYAB and EBNA1 CD4+ T cell responses were detected in natalizumab-treated pwMS. This study provides evidence for antibody cross-reactivity between EBNA1 and CRYAB and points to a similar cross-reactivity in T cells, further demonstrating the role of EBV adaptive immune responses in MS development. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
700 | 1 | a Bronge, Mattiasu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Tengvall, Katarina,d 1980-u Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi,Science for Life Laboratory, SciLifeLab,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut0 (Swepub:uu)katst103 |
700 | 1 | a Akpinar, Birceu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Nilsson, Ola B.u Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Holmgren, Eriku Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Hessa, Tarau Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Gafvelin, Gurou Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Khademi, Mohsenu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Alfredsson, Larsu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.;Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden.4 aut |
700 | 1 | a Martin, Rolandu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.;Univ Zurich, Inst Expt Immunol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.4 aut |
700 | 1 | a Guerreiro-Cacais, Andre Ortliebu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Grönlund, Hansu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Olsson, Tomasu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Kockum, Ingridu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut |
710 | 2 | a Karolinska Institutetb Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 org |
773 | 0 | t Science Advancesd : American Association for the Advancement of Science (AAAS)g 9:20q 9:20x 2375-2548 |
856 | 4 | u https://doi.org/10.1126/sciadv.adg3032y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1776664/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-506588 |
856 | 4 8 | u https://doi.org/10.1126/sciadv.adg3032 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:152861661 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.